Compare ASRT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | XGN |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 71.2M |
| IPO Year | 2004 | 2014 |
| Metric | ASRT | XGN |
|---|---|---|
| Price | $23.49 | $4.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $18.00 | $8.86 |
| AVG Volume (30 Days) | 306.8K | ★ 401.9K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,713,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $12.85 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $2.59 |
| 52 Week High | $23.49 | $12.23 |
| Indicator | ASRT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 83.19 | 57.89 |
| Support Level | $11.05 | $2.68 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | -0.20 | -0.07 |
| Stochastic Oscillator | 86.96 | 36.81 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.